E-mail: sloni01@emory.edu
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
- ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
- ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- ORAL MLN9708, AN INVESTIGATIONAL PROTEASOME INHIBITOR, IN COMBINATION WITH MELPHALAN AND PREDNISONE IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA: A PHASE 1 STUDY
- SECOND PRIMARY MALIGNANCIES (SPM) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ACCORDING TO LENALIDOMIDE EXPOSURE: A META-ANALYSIS OF 6383 INDIVIDUAL PATIENT DATA
- Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD)
- Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
- VANTAGE 088: FINAL RESULTS FROM THE GLOBAL PHASE 3 TRIAL OF THE MULTI-HISTONE DEACETYLASE INHIBITOR VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
- Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial
- Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program
- VORINOSTAT PLUS BORTEZOMIB COMBINATION THERAPY IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: VANTAGE STUDY PROGRAM UPDATE
